text: Major fuel savings have been proved to have been made by not lugging around a full tank if you don’t need to. It works for me!!
  driving economically would seem a no brainer – I once saw a Subaru impreza with a bumper sticker complaing about the cost of fuel!
  (b)Pressure for raising motorway speed limit, coupled with many vehicles already travelling on motorways at well over the legal speed limit.
  (c)Starting the engine and leaving it running for a long time ( often whilst playing around with a mobile phone) before moving off.
  (d)After following behind a vehicle perceived as slow just before leaving a motorway, speeding up to go less than 200 metres on the exit slip and then slamming brakes on when about to join the ordinary non-motorway road system.
  I love it when people say but I don’t use a Car. Or I dont have a Petrol or Diesel car. (Do you Buy your Food from a shop or grow your own? If you buy from a Shop it effects you. If you Power your Electric Car then it’s likely been used to create the Electricity you use to power your car)
  I did not know until reading the section entitled ‘How to keep fuel costs down’ that Asda has any so-called ‘fuel promise’ that its fuel costs would be cheaper than other outlet within 3 miles. About 4 miles from where I live there is an Asda fuel station where diesel costs 115.9 p/ litre and within 0.5 miles of that station there is a Sainsbury’s fuel station which sells diesel for 111.9p/ litre. A further small benefit of choosing the Sainsbury’s option is that Nectar points are also awarded. Incidentally both fuel stations feature in petrolprices.com and the prices quoted there are correct and those prices have remained stable for at least the last two weeks.
  In my above comment I should have used the phrase ‘price promise’ rather than ‘fuel promise,’ also Asda’s promise refers only to fuel stations run by supermarkets rather than to all fuel stations although it is very rare for a non-supermarket outlet to have lower fuel prices than any neighbouring supermarket.
  
  Because of the companionship of pets, a group of people suffering from cancer and depression, gathered together and walked through the most difficult time of their lives. Pets are the messengers of God, spreading love and hope to the earth. We are also looking forward to passing this warmth and sweetness to more and more members. For every dollar you have spent with us, there is a “hope” that will be donated to the local cancer & depression foundations and SPCA of Ontario.
  Animals are reincarnation of wise men. The wisdom accumulated over tens of thousands of years is filled in a body smaller than humans. The dog does not need words, he speaks with the whole body. If you have a dog, be sure to treat him well. He is the only animal in the world that can see God.
  PETS Elite offers various of services including Pets Grooming, Pets Salon, Pets SPA, Events & Training, Membership, Franchise, etc. Feel free to book appointment online or by phone or simply walk in!
  We are preparing our PETS-BOUTIQUE CLUBHOUSE. With our PETS Values and supporting from our energetic members, we believe we will build a beautiful homeland. TO BE EXPECTED!
  
  IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
  NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Company announced previously that Zimura met its pre-specified primary efficacy endpoint and reached statistical significance in GATHER1, also known as OPH2003, the first Phase 3 clinical trial for Zimura for the treatment of GA secondary to AMD. There are no U.S. Food and Drug Administration or European Medicines Agency approved treatments available for patients with GA secondary to AMD.
  “The absence of treatment options for geographic atrophy represents an area of urgent unmet medical need and a major public health concern for the expanding aging population,” stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio. “The initiation of enrollment in GATHER2, brings us another step closer to potentially delivering a clinically meaningful therapy to patients with GA. The GATHER2 clinical trial, if positive, marks the second Phase 3 clinical trial needed to seek regulatory approval for Zimura.”
  “We believe GATHER1 is currently the only Phase 3 clinical trial showing early suppression of GA growth which continued for 18 months with continuous treatment,” stated Kourous A. Rezaei, M.D., Chief Medical Officer of IVERIC bio. “We have experienced impressive enthusiasm by our investigators to initiate the second Phase 3 trial, GATHER2, based on the robustness of efficacy, the strength of the statistical evidence, and the favorable safety profile of Zimura in the GATHER1 Phase 3 trial. We believe that these robust data increase comfort and confidence in our investigators to expedite recruitment and retain patients in our GATHER2 clinical trial.”
  In the GATHER2 clinical trial, approximately 400 patients will be randomized to receive either monthly administration of Zimura 2 mg or sham during the first 12 months of the trial, at which time the primary efficacy analysis of the mean rate of change of GA growth at 12 months will be performed. (Read more…) If the 12 month results are positive, the Company plans to file an application with the U.S. Food and Drug Administration and the European Medicines Agency for marketing approval of Zimura for GA following receipt of that data. At month 12, the Company plans to re-randomize patients in the Zimura 2 mg arm to receive either monthly or every other month administration of Zimura 2 mg. The final evaluation will take place at month 24.
  Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, the advanced stage of AMD, leads to further irreversible loss of vision in these patients. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with geographic atrophy.
  Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of AMD. Zimura is designed to inhibit complement factor C5 cleavage into C5a and C5b. By inhibiting the formation of complement C5 terminal fragments, Zimura may decrease the activation of inflammasomes and the formation of membrane attack complex (MAC). This mechanism of action could potentially prevent or slow down the degeneration of retinal pigment epithelial (RPE) cells and slow down the progression of GA.
  Any statements in this press release about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward looking statements include statements about the impact of the COVID-19 pandemic on the Company’s research and development programs, operations and financial position, its expectations to initiate enrollment in its second Phase 3 trial (GATHER2) of Zimura in geographic atrophy secondary to AMD and to use its previously announced clinical trial of Zimura for the treatment of geographic atrophy (GATHER1) as a Phase 3 trial, its development and regulatory strategy for Zimura, the potential clinical meaningfulness of the results of clinical trials, the Company’s hypotheses regarding complement inhibition as a mechanism of action for the treatment of geographic atrophy, the implementation of its business plan, the timing, progress and results of clinical trials and other research and development activities and the potential utility of its product candidates. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on the Company’s research and development programs, operations and financial position, the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, reliance on collaborators and other third parties, establishment of manufacturing capabilities, expectations for regulatory matters and need for additional financing and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.
  
  This entry was posted in pharma products and tagged franchise of pharma, Pcd Pharma, pharma franchise company, Pharma Pcd Company, pharma products, Top Pharma Franchise Company, Top Pharma Pcd Company by admin. Bookmark the permalink.	
  
  It has been a big year for industry as organisations scramble to be in full compliance with PIC/S PE009-13. With the due date on January 1st 2019, this deadline is coming sooner than many …
  
  Having the right tech set-up makes team members feel proud to come into the office each day, whilst also impressing clients and potential candidates.
  The Philips T-Line awakens curiosity and inspires imagination to help you teach students across all disciplines.
  
  For those of you who are concerned about privacy and big companies tracking you, the focus of those fears tend to be Google and Facebook, but it looks like you have to add Apple to the list as well. A new report is claiming that the iPhone 5s (and likely the new iPads that also feature the M7 coprocessor) can track your movements for up to 4 days after the device's battery dies.
  This is anecdotal and hasn't been confirmed yet, but Reddit user Glarznak has interesting evidence. Apparently, Glarznak was on vacation in Europe and his iPhone battery died. His charging cable had broken, so he decided to just go without his phone for a while. He was also someone who used the Argus app to track his steps. And, when he was finally charged his iPhone, he found that Argus had somehow gotten his movement data for four days after his battery died. This makes it seem as though the M7 motion coprocessor was able to function with the device turned off and using the reserve power in the battery for four days.
  Of course, some will find this to be "creepy", but we try to be more nuanced on these issues. First of all, yes the iPhone continued tracking movements after the battery died, but it only did so because Glarznak had the device set to track him in the first place, which is something you can turn off if you are truly concerned. Also, as we have pointed out before when people complain about Google's policies, this isn't a matter of taking your data, this is a trade where you get value in return. Although, until Apple comments, we don't know what use this feature would be, because the M7 coprocessor is not tied to the GPS, so it would not be tied to "Find My Phone".
  Whatever the explanation, it does prove that users need to be more knowledgeable about their devices, what information is tracked, and what steps to take to opt-out of tracking if that is what you want.